ReviewLeukemia2018
We skip to work: alternative splicing in normal and malignant myelopoiesis.
Review in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- THRAP3 promotes ferroptosis resistance in acute myelocytic leukemia through SLU7-mediated alternative splicing of GIT2.Nature communications · 2025Article
- Post-transcriptional regulation of DEAD-box RNA helicases in hematopoietic malignancies.Genes & diseases · 2024Review
- Integrative alternative splicing analysis reveals new prognosis signature in B-cell acute lymphoblastic leukemia.International journal of biological sciences · 2024Article
- CTCF as a regulator of alternative splicing: new tricks for an old player.Nucleic acids research · 2021Review
- CD44 alternative splicing senses intragenic DNA methylation in tumors via direct and indirect mechanisms.Nucleic acids research · 2021Article
- Characterization of alternative splicing events and prognostic signatures in breast cancer.BMC cancer · 2021Article
- Screening and Identification of Survival-Associated Splicing Factors in Lung Squamous Cell Carcinoma.Frontiers in genetics · 2021Article
- Article
- Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients.Cancers · 2020Article
- In Vivo Validation of Alternative FDXR Transcripts in Human Blood in Response to Ionizing Radiation.International journal of molecular sciences · 2020Article
- Alternative splicing of leptin receptor overlapping transcript in osteosarcoma.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- Identification of novel alternative splicing isoform biomarkers and their association with overall survival in colorectal cancer.BMC gastroenterology · 2020Article
- RNA-Binding Proteins in Acute Leukemias.International journal of molecular sciences · 2020Review
- Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.The Journal of clinical investigation · 2020Review
- Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.Journal of clinical medicine · 2020Article
- Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer.Frontiers in genetics · 2020Article
- Prognostic role of alternative splicing events in head and neck squamous cell carcinoma.Cancer cell international · 2020Article
- Genomics and splicing events of type II endometrial cancers in the black population: racial disparity, socioeconomic and geographical differences.American journal of cancer research · 2020Review
- Survival-Associated Alternative Splicing Events and Prognostic Signatures in Pancreatic Cancer.Frontiers in genetics · 2020Article
- Dido3-dependent SFPQ recruitment maintains efficiency in mammalian alternative splicing.Nucleic acids research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative splicing expands the transcriptome thereby promoting protein diversity. It governs critical cellular processes such as differentiation, proliferation and apoptosis in a tissue-specific manner. Aberrant splicing consequent to mutations in splicing factors and disruption of isoform ratios in key regulatory genes provides an important contribution to the pathogenesis of the myelodysplastic syndromes and myeloid leukemia. We review here the central role of alternative splicing in regulating myelopoiesis, and provide clear examples of how global splicing disruption or specific aberrant splicing events might promote leukemogenesis. We discuss the growing number of mechanistic links between epigenetic factors and alternative splicing. Finally, we address the potential utility of alternatively spliced isoforms as biomarkers and the development of novel therapies that modulate alternative splicing in myeloid and other malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.